Bazedoxifene and Beyond: Identifying This SERM’s Targets and Deciphering Its Molecular Mechanisms
Advances in Pharmacological and Pharmaceutical Sciences · 2026-01 · 2026 (1)
DOI: 10.1155/adpp/3028716 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advances in Pharmacological and Pharmaceutical Sciences, online erschienen am 04.08.2026. Verfasst von Juliette Bherer und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Medicine, Faculty of Medicine, Université Laval, Quebec, Quebec, Canada, ulaval.ca. Die Arbeit nennt 223 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Canadian Institutes of Health Research, Cancer Research Society, Fonds de Recherche du Québec - Santé.
Abstract (Originalsprache)
Bazedoxifene (BZA), a third‐generation selective estrogen receptor modulator (SERM) approved for osteoporosis treatment, is attracting attention for drug repurposing, especially in cancer research. While designed primarily for estrogen receptors, BZA exhibits in vitro off‐target interactions that may explain novel therapeutic benefits or account for potential side effects. This review comprehensively examines both established and newly identified targets of BZA beyond estrogen receptors. To gather relevant data, we reviewed over 1500 articles selecting key studies proposing insights into BZA targets and mechanisms. This review details BZA’s roles in estrogen receptor signaling and its interactions with glycoprotein 130, elaborating on vital components of each signaling pathway. It also compiles its potential interactions with cannabinoid receptors, as well as BZA targets related to biotransformation, absorption/transport, DNA cycle, Sars‐CoV‐2, ferroptosis, ROS production, and cholesterol biosynthesis. For each target, we discuss evidence from computational studies, direct interaction assay, and functional testing. This work provides the most complete overview of BZA’s molecular mechanisms to date and suggests new avenues for future research and potential applications beyond osteoporosis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Molecular Medicine, Faculty of Medicine, Université Laval, Quebec, Quebec, Canada, ulaval.ca.
- Endocrinology and Nephrology Research Program, CHU de Québec-Université Laval Research Center, Quebec, Quebec, Canada.
- Cancer Research Centre, Université Laval, Quebec, Quebec, Canada, ulaval.ca.
- Department of Internal Medicine, Section of Endocrinology and Metabolism, Yale School of Medicine, New Haven, Connecticut, USA, yale.edu.
- Department of Social and Preventive Medicine, Faculty of Medicine, Université Laval, Quebec, Quebec, Canada, ulaval.ca.
- Oncology Research Program, CHU de Québec-Université Laval Research Center, Quebec, Quebec, Canada.
ORCID-Profile: Juliette Bherer, Alisson Clemenceau, Caroline Diorio, Francine Durocher
Förderung
- Canadian Institutes of Health Research
- Cancer Research Society
- Fonds de Recherche du Québec - Santé
- Yale Cancer Center
Zitieren
APA
Bherer, J., Clemenceau, A., Diorio, C., & Durocher, F. (2026). Bazedoxifene and Beyond: Identifying This SERM’s Targets and Deciphering Its Molecular Mechanisms. Advances in Pharmacological and Pharmaceutical Sciences, 2026(1). https://doi.org/10.1155/adpp/3028716
Vancouver
Bherer J, Clemenceau A, Diorio C, Durocher F. Bazedoxifene and Beyond: Identifying This SERM’s Targets and Deciphering Its Molecular Mechanisms. Advances in Pharmacological and Pharmaceutical Sciences. 2026;2026(1). doi:10.1155/adpp/3028716
BibTeX
@article{Bherer2026,
author = {Bherer, Juliette and Clemenceau, Alisson and Diorio, Caroline and Durocher, Francine},
title = {Bazedoxifene and Beyond: Identifying This SERM’s Targets and Deciphering Its Molecular Mechanisms},
journal = {Advances in Pharmacological and Pharmaceutical Sciences},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/adpp/3028716}
}
EUVIMED